HF-REVERT
Phase 2, Multicentre, Randomised, Double-blind, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction (≤45%) After Myocardial Infarction
- Stage
- klaar
- Medicine
- CDR132L
- Population
- ASCVD
- Phase
- II
- First Patient In
- 30 June 2022
- Last Patient In
- 4 March 2024
- Last Patient Last Visit
- 17 March 2025
National Lead
prof. dr. R.A. de Boer
Cardioloog
Study Director
dr. T. Oosterhof
Cardioloog
Office Contact
